Benzodiazepines (BZs) and selective serotonin reuptake inhibitors (SSRIs) are effective in the pharmacologic treatment of panic disorder (PD). However, treatment guidelines favor SSRIs over BZs based on the belief that BZs are associated with more adverse effects than SSRIs. This belief, however, is currently supported only by opinion and anecdotes.
Aim:
The aim of this review and meta-analysis was to determine if there truly is evidence that BZs cause more adverse effects than SSRIs in acute PD treatment.
Methods:
We systematically searched Web of Science, PubMed, Cochrane Central Register of Controlled Trials, and clinical trials register databases. Short randomized clinical trials of a minimum of four weeks and a maximum of 12 weeks that studied SSRIs or BZs compared to placebo in acute PD treatment were included in a meta-analysis. The primary outcome was all-cause adverse event rate in participants who received SSRIs, BZs, or placebo.
Results:
Overall, the meta-analysis showed that SSRIs cause more adverse events than BZs in short-term PD treatment. Specifically, SSRI treatment was a risk factor for diaphoresis, fatigue, nausea, diarrhea, and insomnia, whereas BZ treatment was a risk factor for memory problems, constipation, and dry mouth. Both classes of drugs were associated with somnolence. SSRIs were associated with abnormal ejaculation, while BZs were associated with libido reduction. BZs were protective against tachycardia, diaphoresis, fatigue, and insomnia.
Conclusion:
Randomized, blinded studies comparing SSRIs and BZs for the short-term treatment of PD should be performed. Clinical guidelines based on incontrovertible evidence are needed.
Ait-DaoudNHambyASSharmaS, et al. (2018) A review of alprazolam use, misuse, and withdrawal. J Addict Med12: 4.
2.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Revised. Washington, DC: American Psychiatric Association.
3.
American Psychiatric Association (1998) Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. Am J Psychiatry155: 1–34.
4.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders. 5th ed.Washington, DC: American Psychiatric Association.
5.
American Psychiatric Association Task (1990) Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association.
6.
AnderschSRosenbergNKullingsjöH, et al. (1991) Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand83(Suppl 365): 18–27.
AshtonH (2005) The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry18: 249–255.
9.
AsnisGHameediFGoddardA, et al. (2001) Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatr Res103: 1–14.
10.
BaldwinDSAndersonIMNuttDJ, et al. (2014) Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol28: 403–439.
11.
BallengerJWheadonDSteinerM, et al. (1998) Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatr155: 36–42.
12.
BalonRChouinardGCosciF, et al. (2018) International task force on benzodiazepines. Psychother Psychosom87: 193–194.
13.
BalonRFavaGARickelsK (2015) Need for a realistic appraisal of benzodiazepines. World Psychiatry14: 243–244.
14.
BandelowBZoharJHollanderE, et al. (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders–first revision. World J Biol Psychiatry9: 248–312.
15.
BandelowBMichaelisS (2015) Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci17: 327.
16.
BeauclairLFontaineRAnnableL, et al. (1994) Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol14: 111–118.
17.
BelaiseCGattiAChouinardVA, et al. (2012) Patient online report of selective serotonin reuptake inhibitor-induced persistent postwithdrawal anxiety and mood disorders. Psychother Psychosom81: 386–388.
18.
BeracocheaD (2006) Anterograde and retrograde effects of benzodiazepines on memory. ScientificWorldJournal6: 1460–1465.
19.
BhanjiNHChouinardGKolivakisT, et al. (2006) Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Can J Clin Pharmacol13: e69–74.
20.
BruceSEVasileRGGoismanRM, et al. (2003) Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?Am J Psychiatry160: 1432–1438.
21.
CarriereIFourrier-ReglatADartiguesJF, et al. (2009) Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med169: 1317–1324.
22.
CassanoGToniCPetraccaA, et al. (1994) Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. Euro Neuropsychopharmacol4: 47–53.
23.
CelliniN (2017) Memory consolidation in sleep disorders. Sleep Med Rev35: 101–112.
24.
CosciFGuidiJBalonR, et al. (2015) Clinical methodology matters in epidemiology: not all benzodiazepines are the same. Psychother Psychosom84: 262–262.
25.
CosgroveLKrimskyS (2012) A comparison of DSM-IV and DSM-5 panel members’ financial associations with industry: a pernicious problem persists. PLoS Med9: e1001190.
26.
ChouinardGChouinardV-A (2015) New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom84: 63–71.
27.
ClarkDMSalkovskisPMÖstL-G, et al. (1997) Misinterpretation of body sensations in panic disorder. J Consult Clin Psychol65: 203.
28.
Cross-National Collaborative Panic Study (1992) Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry191–202; discussion 202–195.
29.
CsokaABShipkoS (2006) Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom75: 187–188.
30.
Dell’OssoBAlbertUAttiAR, et al. (2015) Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatr Dis Treat11: 1885.
31.
DerSimonianRLairdN (1986) Meta-analysis in clinical trials. Control Clin Trials7: 177–188.
32.
DmitrievKVFedorovaVINedostupAV (2001) Clonazepam in the treatment of labile arterial hypertension in the elderly. Ter Arkh73: 58–61.
33.
EvansEASullivanMA (2014) Abuse and misuse of antidepressants. Subst Abuse Rehabil5: 107.
34.
FavaGAGattiABelaiseC, et al. (2015) Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom84: 72–81.
35.
FavaM (2006) Prospective studies of adverse events related to antidepressant discontinuation. J Clinical Psychiatry67: 14–21.
36.
GouldTJ (2010) Addiction and cognition. Addict Sci Clin Pract5: 4.
GreenblattDJShaderRUAbernethyDR (1983) Current status of benzodiazepines (first of two parts). N Engl J Med309: 354–358.
39.
GriffinCEIIIKayeAMBuenoFR, et al. (2013) Benzodiazepine pharmacology and central nervous system–mediated effects. Ochsner J13: 214–223.
40.
HaddadP (1998) The SSRI discontinuation syndrome. J Psychopharmacol12: 305–313.
41.
HigginsJPAltmanDGGøtzschePC, et al. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ343: d5928.
42.
Hoehn-SaricRMcLeodDHipsleyP (1993) Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol13: 321–326.
43.
HsuJHShenWW (1995) Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Intern J Psychiatry Med25: 191–201.
44.
Huedo-MedinaTBSanchez-MecaJMarin-MartinezF, et al. (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index?Psychol Methods11: 193–206.
45.
KahnJPVerasABNardiAE, et al. (2019) Clonazepam treatment of atrial fibrillation in panic anxiety patients: a case series. Psychosomatics60: 528–532.
46.
KalmbachDACieslaJAJanataJW, et al. (2012) Specificity of anhedonic depression and anxious arousal with sexual problems among sexually healthy young adults. J Sex Med9: 505–513.
47.
KhawamEALaurencicGMaloneDAJr (2006) Side effects of antidepressants: an overview. Clev Clin J Med73: 351–361.
48.
LecrubierYBakkerADunbarG, et al. (1997) A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder: Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand95: 145–152.
49.
LintonKDWylieKR (2010) Recent advances in the treatment of premature ejaculation. Drug Des Devel Ther4: 1.
50.
LondborgPWolkowRSmithW, et al. (1998) Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry173: 54–60.
51.
LydiardRLesserIBallengerJ, et al. (1992) A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol12: 96–103.
52.
MeuretAEWolitzky-TaylorKBTwohigMP, et al. (2012) Coping skills and exposure therapy in panic disorder and agoraphobia: latest advances and future directions. Behav Ther43: 271–284.
53.
MichelsonDAllgulanderCBjorlingG, et al. (2000) Fluoxetine in panic disorder: a randomized, placebo-controlled study. Eur Neuropsychopharmacol10: 165–169.
54.
MontejoALLlorcaGIzquierdoJA, et al. (2001) Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry62(Suppl 3): 10–21.
55.
Montejo-GonzalezALLlorcaGIzquierdoJA, et al. (1997) SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther23: 176–194.
56.
NardiAECosciFBalonR, et al. (2018) The prescription of benzodiazepines for panic disorder: time for an evidence-based educational approach. J Clin Psychopharmacol38: 283–285.
57.
NardiAEFreireRCValençaAM, et al. (2010) Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol30: 290–293.
58.
National Institute for Health and Care Excellence (2011) Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. NICE Clinical Guideline 113. Manchester, UK: National Institute for Health and Care Excellence.
59.
NeumanJKorensteinDRossJS, et al. (2011) Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ343: d5621.
60.
NielsenMHansenEHGotzschePC (2012) What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction107: 900–908.
61.
NoyesRDuPontRPecknoldJ, et al. (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry45: 423–428.
OffidaniEGuidiJTombaE, et al. (2013) Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom82: 355–362.
64.
PecknoldJLutheLMunjackD, et al. (1994) A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol14: 314–321.
65.
PohlRWolkowRClaryC (1998) Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry155: 1189–1195.
66.
PollackMOttoMWorthingtonJ, et al. (1998) Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry55: 1010–1016.
67.
QuagliatoL (2018) Selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines (BZDs) in panic disorder (PD) treatment: a meta-analysis of harms. PROSPERO 2018 CRD42018104339. Available at: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018104339 (accessed 7 August 2018).
68.
QuagliatoLAFreireRCNardiAE (2018) Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines. Expert Opin Drug Saf17: 315–324.
69.
R Consortium Team (2013) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
70.
RichardsonWSWilsonMCNishikawaJ, et al. (1995) The well-built clinical question: a key to evidence-based decisions. ACP J Club123: A12–A13.
71.
RickelsKSchweizerECaseWG, et al. (1990) Long-term therapeutic use of benzodiazepines: I. Effects of abrupt discontinuation. Arch Gen Psychiatry47: 899–907.
72.
RosenbaumJFFavaMHoogSL, et al. (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry44: 77–87.
SandmannJLorchBBandelowB, et al. (1995) Effect of fluvoxamine in panic disorder: a double-blind placebo-controlled study. Pharmacopsychiatry28: 253–256.
75.
SchweizerERickelsKCaseWG, et al. (1990) Long-term therapeutic use of benzodiazepines: II. Effects of gradual taper. Arch Gen Psychiatry47: 908–915.
76.
SheikhJLondborgPClaryC, et al. (2000) The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Intern Clin Psychopharmacol15: 335–342.
StahlSGergelILiD (2003) Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry64: 1322–1327.
79.
StanbrookMB (2012) Addiction is a disease: we must change our attitudes toward addicts. Can Med Assoc J184: 155.
80.
StarcevicV (2009) Anxiety Disorders in Adults: A Clinical Guide. New York: Oxford University Press.
81.
StarcevicV (2012a) Benzodiazepines for anxiety disorders: maximising the benefits and minimising the risks. Adv Psychiatr Treat18: 250–258.
82.
StarcevicV (2012b) Reconsidering benzodiazepines in the treatment of panic disorder. Aust N Z J Psychiatry46: 271–272.
83.
StarcevicV (2014) The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother14: 1275–1286.
84.
StewartSA (2005) The effects of benzodiazepines on cognition. J Clin Psychiatry66(Suppl 2): 9–13
85.
TolinDF (2017) Can cognitive behavioral therapy for anxiety and depression be improved with pharmacotherapy? A meta-analysis. Psychiatr Clin North Am40: 715–738.
86.
TurnerEHKnoepflmacherDShapleyL (2012) Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med9: e1001189.
87.
TveteIFBjornerTAursnesIA, et al. (2013) A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. BMJ3: e003296.
88.
ValençaANardiANascimentoI, et al. (2000) Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr58: 1025–1029.
89.
VemulapalliSBarlettaM (1984) The role of the sympathetic nervous system in the cardiovascular effects of systemically administered gamma-aminobutyric acid. Arch Int Pharmacodyn Ther267: 46–58.
90.
VerdouxHLagnaouiRBegaudB (2005) Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med35: 307–315.
91.
WadeALepolaUKoponenH, et al. (1997) The effect of citalopram in panic disorder. Br J Psychiatry170: 549–553.
92.
WhittingtonCJKendallTFonagyP, et al. (2004) Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet363: 1341–1345.
93.
WuTXLiYPLiuGJ, et al. (2006) Investigation of authenticity of ‘claimed’ randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. Presented at XIV Cochrane Colloquium, Dublin, Ireland, 23–26October2006.
94.
ZagmuttFJTarrantsML (2012) Indirect comparisons of adverse events and dropout rates in early Parkinson’s disease trials of pramipexole, ropinirole, and rasagiline. Int J Neurosci122: 345–353.
95.
ZorzelaLLokeYKIoannidisJP, et al. (2016) PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ352: i157.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
